Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China

[1]  C. Mazzucco,et al.  Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.

[2]  A. Cross,et al.  Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. , 2006, Gastroenterology.

[3]  E. Schiff,et al.  A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. , 2005, Gastroenterology.

[4]  Y. Liaw,et al.  Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[5]  Z. Abbas,et al.  Hepatology issues in Asia: Perspectives from regional leaders , 2004 .

[6]  Ching-lung Lai,et al.  Four years of lamivudine treatment in Chinese patients with chronic hepatitis B , 2004, Journal of gastroenterology and hepatology.

[7]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[8]  Sheng-Nan Lu,et al.  Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. , 2004, Journal of Hepatology.

[9]  Y. Liaw,et al.  No Benefit to Continue Lamivudine Therapy after Emergence of Ymdd Mutations , 2004, Antiviral therapy.

[10]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[11]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[12]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[13]  R. J. Colonno,et al.  Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[14]  Jianhua Lu,et al.  Prevention and control of hepatitis B in China , 2002, Journal of medical virology.

[15]  S. Hadziyannis,et al.  Course of virologic breakthroughs under long‐term lamivudine in HBeAg‐negative precore mutant HBV liver disease , 2002, Hepatology.

[16]  R. D. de Man,et al.  The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[17]  N. Leung.  Clinical Experience With Lamivudine , 2002, Seminars in liver disease.

[18]  F. Zoulim.  Detection of hepatitis B virus resistance to antivirals. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[19]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[20]  G. Lau.  Hepatitis B infection in China. , 2001, Clinics in liver disease.

[21]  R. Schinazi,et al.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.

[22]  Y. Liaw.  Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. , 2001, Antiviral chemistry & chemotherapy.

[23]  J. Hoofnagle,et al.  Long‐term therapy of chronic hepatitis B with lamivudine , 2000, Hepatology.

[24]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[25]  Ally,et al.  A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B , 2000 .

[26]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[27]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[28]  K. Chayama,et al.  Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.

[29]  R. Colonno,et al.  Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus , 1997, Antimicrobial agents and chemotherapy.